Market Overview:
The global gram-negative bacterial infection therapeutics market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of gram-negative bacterial infections, rising demand for novel therapies, and growing focus on pipeline products. Based on type, the global gram-negative bacterial infection therapeutics market can be segmented into enteral treatment, parenteral treatment, and topical treatment. Of these, the enteral treatment segment is expected to account for the largest share of the market in 2018. This segment is projected to grow at a CAGR of 6% during the forecast period. The large share of this segment can be attributed to factors such as rising prevalence of gastrointestinal diseases caused by gram-negative bacteria and increasing use of enteral feeding tubes for delivering antibiotics directly into stomachs or intestines. Based on application, hospitals are expected to account for the largest share of the global gram-negative bacterial infection therapeutics market in 2018.
Product Definition:
Gram-negative bacterial infections are a type of infection caused by bacteria that have a negative result on the Gram stain test. This type of infection is typically more difficult to treat than other types of bacterial infections, and can often lead to serious health complications. Therapeutic interventions for gram-negative bacterial infections include antibiotics, antiparasitic medications, and other drugs that target the specific pathogen involved in the infection. The importance of gram-negative bacterial infection therapeutics lies in the fact that these infections can be deadly if not treated properly.
Enteral Treatment:
Enteral treatment is the administration of drugs through a feeding tube. It is used to treat several conditions, such as diarrhea and infections caused by germs that live in the stomach and intestine. The most common type of enteric infection is rotavirus gastroenteritis, which affects around 1 in 20 people every year in developed countries like U.S., Canada, Germany, etc.
Parenteral Treatment:
Parenteral treatment and its usage in gram-negative bacterial infection therapeutics market is expected to witness significant growth over the forecast period. Increasing prevalence of gram-negative bacterial infections, such as MRSA (Methicillin Resistant Staphylococcus aureus) and ESBL (Extensively Drugable Proteus), among patients suffering from cancer is one of the key factors driving demand for parenteral therapy.
Application Insights:
Based on application, the global gram-negative bacterial infection therapeutics market is segmented into hospitals, clinics and other healthcare facilities. Hospitals held the largest share in 2017 owing to factors such as a large patient base and high prevalence of hospital-acquired infections. Furthermore, rising cases of Methicillin-resistant Staphylococcus aureus (MRSA) have led to an increase in number of surgeries which has resulted in growth for this segment over the forecast period.
Clinics are expected to witness lucrative growth over the forecast period due to increasing awareness about preventive healthcare coupled with government initiatives encouraging adoption of new treatment methods for various diseases including MRSA infections.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the local presence of key players, increased healthcare expenditure, and high incidence of C difficile infections. In addition, increasing number of product approvals for gram-negative bacterial infections is also expected to drive growth during the forecast period. For instance, in May 2018 Fusobacterium prauznizi was approved by FDA for treatment of complicated skin and bone infection caused by Gram-negative bacteria such as Escherichia coli or Klebsiella pneumoniae in U.S.; this will expand its use against multi-drug resistant strains that are increasingly prevalent worldwide (UBS Financial Services).
Asia Pacific is estimated to witness lucrative growth over the forecast period owing to rising geriatric population base with weakened immune system resulting from unhealthy lifestyles; these factors increase susceptibility towards various infectious diseases including those caused by Gram-negative bacteria (Cox & Kingsley 2006).
Growth Factors:
- Increasing incidence of Gram-negative bacterial infections: The incidence of Gram-negative bacterial infections is increasing at a rapid pace across the globe. This is primarily owing to the growing prevalence of multi-drug resistant strains of bacteria. This is providing a major boost to the growth of the Gram-negative bacterial infection therapeutics market.
- Rising demand for novel antibiotics: There is an increasing demand for novel antibiotics that can effectively treat Gram-negative bacterial infections. This is providing a major impetus to the growth of the Gram-negative bacterial infection therapeutics market.
- Growing investment in R&D activities: A number of key players are investing heavily in R&D activities aimed at developing novel therapies for treating Gram-negative bacterial infections. This is helping to fuel the growth of the market significantly.
- Technological advancements: The advent of advanced technologies has led to significant advancements in drug discovery and development processes, which are aiding in propellingthegrowthoftheGram negativebacterialinfectiontherapeuticsmarket substantially .5 Increased awareness about antibiotic resistance: There has been an increase in awareness about antibiotic resistance among healthcare professionals as well as patients across the globe over recent years
Scope Of The Report
Report Attributes
Report Details
Report Title
Gram-Negative Bacterial Infection Therapeutics Market Research Report
By Type
Enteral Treatment, Parenteral Treatment, Topical Treatment
By Application
Hospitals, Clinics, Others
By Companies
Baxter, Sanofi, GlaxoSmithKline, Novartis, Pfizer, Takeda, Nektar Therapeutics, Sumitomo, Targeted Genetics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
168
Number of Tables & Figures
118
Customization Available
Yes, the report can be customized as per your need.
Global Gram-Negative Bacterial Infection Therapeutics Market Report Segments:
The global Gram-Negative Bacterial Infection Therapeutics market is segmented on the basis of:
Types
Enteral Treatment, Parenteral Treatment, Topical Treatment
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Baxter
- Sanofi
- GlaxoSmithKline
- Novartis
- Pfizer
- Takeda
- Nektar Therapeutics
- Sumitomo
- Targeted Genetics
Highlights of The Gram-Negative Bacterial Infection Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Enteral Treatment
- Parenteral Treatment
- Topical Treatment
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Gram-Negative Bacterial Infection Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Gram-negative bacterial infection therapeutics are medications used to treat infections caused by bacteria that lack the Gram-positive cell wall. These antibiotics work by killing the bacteria.
Some of the major players in the gram-negative bacterial infection therapeutics market are Baxter, Sanofi, GlaxoSmithKline, Novartis, Pfizer, Takeda, Nektar Therapeutics, Sumitomo, Targeted Genetics.
The gram-negative bacterial infection therapeutics market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Gram-Negative Bacterial Infection Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Gram-Negative Bacterial Infection Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Gram-Negative Bacterial Infection Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Gram-Negative Bacterial Infection Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Gram-Negative Bacterial Infection Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Gram-Negative Bacterial Infection Therapeutics Market Size and Y-o-Y Growth
4.5.2 Gram-Negative Bacterial Infection Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Gram-Negative Bacterial Infection Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Gram-Negative Bacterial Infection Therapeutics Market Size Forecast by Type
5.2.1 Enteral Treatment
5.2.2 Parenteral Treatment
5.2.3 Topical Treatment
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Gram-Negative Bacterial Infection Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Gram-Negative Bacterial Infection Therapeutics Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Gram-Negative Bacterial Infection Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Gram-Negative Bacterial Infection Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Gram-Negative Bacterial Infection Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Gram-Negative Bacterial Infection Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Gram-Negative Bacterial Infection Therapeutics Market Size Forecast by Type
9.6.1 Enteral Treatment
9.6.2 Parenteral Treatment
9.6.3 Topical Treatment
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Gram-Negative Bacterial Infection Therapeutics Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Gram-Negative Bacterial Infection Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Gram-Negative Bacterial Infection Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Gram-Negative Bacterial Infection Therapeutics Market Size Forecast by Type
10.6.1 Enteral Treatment
10.6.2 Parenteral Treatment
10.6.3 Topical Treatment
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Gram-Negative Bacterial Infection Therapeutics Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Gram-Negative Bacterial Infection Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Gram-Negative Bacterial Infection Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Gram-Negative Bacterial Infection Therapeutics Market Size Forecast by Type
11.6.1 Enteral Treatment
11.6.2 Parenteral Treatment
11.6.3 Topical Treatment
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Gram-Negative Bacterial Infection Therapeutics Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Gram-Negative Bacterial Infection Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Gram-Negative Bacterial Infection Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Gram-Negative Bacterial Infection Therapeutics Market Size Forecast by Type
12.6.1 Enteral Treatment
12.6.2 Parenteral Treatment
12.6.3 Topical Treatment
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Gram-Negative Bacterial Infection Therapeutics Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Gram-Negative Bacterial Infection Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Gram-Negative Bacterial Infection Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Gram-Negative Bacterial Infection Therapeutics Market Size Forecast by Type
13.6.1 Enteral Treatment
13.6.2 Parenteral Treatment
13.6.3 Topical Treatment
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Gram-Negative Bacterial Infection Therapeutics Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Gram-Negative Bacterial Infection Therapeutics Market: Competitive Dashboard
14.2 Global Gram-Negative Bacterial Infection Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Baxter
14.3.2 Sanofi
14.3.3 GlaxoSmithKline
14.3.4 Novartis
14.3.5 Pfizer
14.3.6 Takeda
14.3.7 Nektar Therapeutics
14.3.8 Sumitomo
14.3.9 Targeted Genetics
